A Nested Case–Control Study on Treatment-related Risk Factors for Early Relapse of Tuberculosis
- 15 November 2004
- journal article
- research article
- Published by American Thoracic Society in American Journal of Respiratory and Critical Care Medicine
- Vol. 170 (10), 1124-1130
- https://doi.org/10.1164/rccm.200407-905oc
Abstract
This nested case-control study aimed at evaluating treatment-related risk factors of relapse of tuberculosis under a service program of directly observed treatment. Out of 12,183 patients with pulmonary tuberculosis who completed treatment within 1 year, 113 relapsed within 30 months after commencement of therapy. The overall 30-month relapse rate was 0.9% (95% confidence interval [CI] 0.8-1.1%). On matching 113 cases with 226 control subjects in a conditional logistic model, thrice-weekly treatment increased the risk of relapse in comparison with daily treatment (odds ratio 3.92, 95% CI 1.78-8.63), whereas prolonging both intensive phase and overall treatment by 50% or more protected against relapse (odds ratio 0.24, 95% CI 0.08-0.70). When pretreatment culture was positive and cavitation was absent, the 30-month relapse rate for standard thrice-weekly regimen was 1.1% (95% CI 0.6-2.0%). The corresponding rates in the presence of cavitation were 7.8% (95% CI 4.0-14.6%) for standard thrice-weekly regimen; 3.3% (95% CI 1.9-5.5%) for standard daily regimen; 0.5% (95% CI 0.1-2.6%) for extended thrice-weekly regimen; and 0.4% (95% CI 0.1-0.9%) for extended daily regimen. Further studies are required to reduce the risk of relapse under program settings.Keywords
This publication has 15 references indexed in Scilit:
- American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of AmericaAmerican Journal of Respiratory and Critical Care Medicine, 2003
- Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trialThe Lancet, 2002
- A Prospective, Randomized, Double-Blind Study of the Tolerability of Rifapentine 600, 900, and 1,200 mg Plus Isoniazid in the Continuation Phase of Tuberculosis TreatmentAmerican Journal of Respiratory and Critical Care Medicine, 2002
- Pulmonary Tuberculosis in HIV-Infected Patients in Zaire — A Controlled Trial of Treatment for Either 6 or 12 MonthsNew England Journal of Medicine, 1995
- Assessment of New Sterilizing Drugs for Treating Pulmonary Tuberculosis by Culture at 2 MonthsAmerican Review of Respiratory Disease, 1993
- A Controlled Clinical Comparison of 6 and 8 Months of Antituberculosis Chemotherapy in the Treatment of Patients with Silicotuberculosis in Hong KongAmerican Review of Respiratory Disease, 1991
- Five-Year Follow-Up of a Controlled Trial of Five 6-Month Regimens of Chemotherapy for Pulmonary TuberculosisAmerican Review of Respiratory Disease, 1987
- The experimental paradigm and observational studies of cause-effect relationships in clinical medicineJournal of Chronic Diseases, 1987
- Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis Second reportTubercle, 1980
- A comparative study of daily followed by twice- or once-weekly regimens of ethambutol and rifampicin in the retreatment of patients with pulmonary tuberculosis: Second reportTubercle, 1976